Seven languages, one version of the truth.
We build multilingual pharmaceutical websites where product ranges, country availability and regulatory content stay consistent across every language version, instead of drifting apart the moment the first market updates a specification on its own.
The failure mode is always the same: each market edits its own version, the technical data diverges, and two years later the German page and the Spanish page describe the same product differently. In a regulated sector that is not untidy, it is a compliance exposure.
A content model that separates translatable copy from shared technical data, country availability as structured data, language and region targeting, and a publishing workflow local teams can use without breaking the shared layer.
We build the structure that translated content lives in and work alongside your translators or linguistic reviewers, so the technical layer is ready the moment the language is.
What our multilingual pharmaceutical website work has had to keep consistent.
For a distributor it is the specification. For a laboratory it is the indication. Multilingual pharmaceutical websites start from what must never diverge.
What comes up when a pharma site has to exist in several languages.
No, and we are explicit about that boundary in scope from the start. Translation and linguistic review sit with a specialist supplier or your own local teams, not with us. We build the structure the translated content lives in and manage the publishing workflow around it, including review and approval steps.
By separating shared technical data from translatable copy in the content model. A specification is stored once and rendered in every language, so a local edit cannot change a fact. Only the copy layer is editable per market, which is exactly the layer that should be.
Almost always because language and region targeting was never declared properly, or because each market published near-identical content without a canonical strategy. It is a technical problem with a technical fix, and adding more local content usually makes it worse rather than better.
If the model was built for it, yes: adding a market becomes content and configuration work rather than a rebuild. That is the point of defining availability and language handling at the start, instead of treating the second or third language as a later phase to be solved when it arrives.
Multilingual work usually arrives with a migration or a catalogue rebuild attached. These are the services it most often sits with.
A new market, a catalogue that has diverged between languages, or country sites competing with each other. Tell us the context and we will tell you how we would approach the multilingual pharmaceutical website work.